IMMNOV.ST - Immunovia AB (publ)

Stockholm - Stockholm Real Time Price. Currency in SEK
+0.50 (+0.57%)
At close: 5:29PM CET
Stock chart is not supported by your current browser
Previous Close87.40
Bid89.10 x 0
Ask90.50 x 0
Day's Range86.30 - 90.40
52 Week Range75.50 - 123.25
Avg. Volume18,312
Market Cap1.522B
PE Ratio (TTM)N/A
EPS (TTM)-2.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire8 months ago

    Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston

    A highly skilled team with a proven track record of successfully establishing and scaling up CLIA accredited reference laboratories based on ground breaking new technologies have been recruited to carry out the US market introduction of Immunovia's first test, IMMray™ PanCan-d, in the second half of 2018. Mats Grahn, CEO Immunovia, comments: "The market introduction of IMMray™ PanCan-d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia.

  • We're sorry this is all we were able to find about this topic.